Staphylococcal Scalded Skin Syndrome (SSSS)
Published on September 18, 2026
Risk Factors
Neonates and children under 5 years old; adults with renal insufficiency or immunosuppression; immature renal clearance of exotoxins; lack of anti-exotoxin antibodies
Etiology
Exfoliative toxins A and B (ETA/ETB) produced by Staphylococcus aureus phage group II; toxins act as serine proteases that cleave desmoglein-1 in the granular layer of the epidermis
Presentation
Irritable child with diffuse, tender erythema ("sunburn-like") that rapidly progresses to superficial flaccid bullae and widespread sheet-like desquamation; fever and skin tenderness often precede the rash
Classic Exam
Diffuse erythroderma with wrinkling and peeling of skin on gentle lateral pressure (positive Nikolsky sign); perioral crusting and fissuring; no mucosal involvement; skin has a "scalded" or "sandpaper to tissue-paper" texture
Diagnostics
Skin biopsy (frozen section) showing cleavage plane through the granular layer of the epidermis without necrotic keratinocytes; cultures from the primary infection site (not the bullae) grow S. aureus; bullae fluid is sterile
Management
IV antistaphylococcal penicillin (nafcillin or oxacillin); vancomycin if MRSA is suspected; aggressive fluid resuscitation and wound care; no systemic corticosteroids
Keywords
"Scalded appearance," "positive Nikolsky sign," "no mucous membrane involvement," "sterile bullae," "perioral crusting," "superficial cleavage plane," "neonate or young child," "tender erythroderma"
01Pathophysiology
Staphylococcal Scalded Skin Syndrome (SSSS) is a toxin-mediated disease, not a direct infection of the skin at the sites of desquamation. Staphylococcus aureus belonging to phage group II colonizes or infects a distant site, which can be the nasopharynx, the conjunctivae, the umbilicus in neonates, or a wound. From that localized focus, the organism produces exfoliative toxins A and B (ETA and ETB), which enter the bloodstream and disseminate hematogenously.
These exfoliative toxins function as serine proteases that cleave desmoglein-1 (Dsg-1), a desmosomal adhesion molecule concentrated in the granular layer (stratum granulosum) of the epidermis. Dsg-1 is responsible for cell-to-cell adhesion between keratinocytes in the superficial epidermis. When Dsg-1 is proteolytically destroyed, keratinocytes lose adhesion, and the epidermis splits within the granular layer. This produces widespread, superficial, intra-epidermal cleavage. Because the split is superficial, the blister roof is extremely thin, ruptures easily, and leaves behind moist, red, denuded skin that looks as though it has been scalded by hot water.
The reason neonates and young children are disproportionately affected relates to two factors. First, they have immature renal function and cannot efficiently clear the circulating exotoxins, which allows toxin levels to reach a threshold that causes widespread disease. Second, young children lack protective IgG antibodies against ETA and ETB. Adults develop neutralizing antibodies over time through subclinical exposures, which is why adult SSSS is rare and almost exclusively seen in patients with chronic renal failure (who cannot excrete the toxin) or immunosuppression (who cannot mount a neutralizing antibody response).
The positive Nikolsky sign (lateral pressure on uninvolved skin produces epidermal separation) is a direct consequence of the weakened Dsg-1 bonds throughout the granular layer. It reflects the fragility of the superficial epidermis due to toxin-mediated cleavage.
A critical teaching point is why there is no mucous membrane involvement. Mucosal epithelium expresses desmoglein-3 (Dsg-3) in addition to Dsg-1. Dsg-3 provides a compensatory adhesion that the exfoliative toxins do not target. This is the single most important distinguishing feature from toxic epidermal necrolysis (TEN), where full-thickness epidermal necrosis destroys the dermoepidermal junction and mucous membranes are prominently involved.
02Classification and Clinical Manifestation
SSSS exists on a clinical spectrum. The following table outlines the recognized forms from localized to generalized:
Bullous Impetigo
Description
Localized form of exfoliative toxin-mediated disease
Key Features
Discrete, flaccid bullae on an erythematous base, usually on the trunk or extremities; toxin acts locally rather than systemically; culture of blister fluid is positive (unlike generalized SSSS)
Generalized SSSS (Scarlatiniform Stage)
Description
Early phase of disseminated toxin-mediated disease
Key Features
Diffuse, tender erythroderma with a "sandpaper" texture; skin becomes painful to touch; perioral erythema and fissuring ("radial crusting"); no bullae yet
Generalized SSSS (Exfoliative Stage)
Description
Fully developed disease
Key Features
Large, flaccid, sterile bullae form over erythematous skin; Nikolsky sign is positive; sheets of superficial epidermis slough off, leaving glistening, moist, red denuded areas; resembles a scald or burn
Generalized SSSS (Desquamative/Recovery Stage)
Description
Healing phase
Key Features
Superficial desquamation dries and peels off in large sheets; re-epithelialization occurs within 7 to 14 days without scarring because the basement membrane and dermis are intact
Form | Description | Key Features |
|---|---|---|
Bullous Impetigo | Localized form of exfoliative toxin-mediated disease | Discrete, flaccid bullae on an erythematous base, usually on the trunk or extremities; toxin acts locally rather than systemically; culture of blister fluid is positive (unlike generalized SSSS) |
Generalized SSSS (Scarlatiniform Stage) | Early phase of disseminated toxin-mediated disease | Diffuse, tender erythroderma with a "sandpaper" texture; skin becomes painful to touch; perioral erythema and fissuring ("radial crusting"); no bullae yet |
Generalized SSSS (Exfoliative Stage) | Fully developed disease | Large, flaccid, sterile bullae form over erythematous skin; Nikolsky sign is positive; sheets of superficial epidermis slough off, leaving glistening, moist, red denuded areas; resembles a scald or burn |
Generalized SSSS (Desquamative/Recovery Stage) | Healing phase | Superficial desquamation dries and peels off in large sheets; re-epithelialization occurs within 7 to 14 days without scarring because the basement membrane and dermis are intact |
Staging of clinical progression:
Prodrome
Timeline
Day 0 to 1
Clinical Appearance
Fever, irritability, skin tenderness; possible upper respiratory or conjunctival infection at a distant site
Erythroderma
Timeline
Day 1 to 2
Clinical Appearance
Diffuse, scarlatiniform erythema starting on the face, neck, axillae, and groin; perioral crusting
Bullous/Exfoliative
Timeline
Day 2 to 3
Clinical Appearance
Flaccid, superficial bullae; positive Nikolsky sign; skin sloughing in sheets
Desquamation
Timeline
Day 3 to 5
Clinical Appearance
Dry, flaking desquamation
Resolution
Timeline
Day 7 to 14
Clinical Appearance
Complete healing without scarring
Stage | Timeline | Clinical Appearance |
|---|---|---|
Prodrome | Day 0 to 1 | Fever, irritability, skin tenderness; possible upper respiratory or conjunctival infection at a distant site |
Erythroderma | Day 1 to 2 | Diffuse, scarlatiniform erythema starting on the face, neck, axillae, and groin; perioral crusting |
Bullous/Exfoliative | Day 2 to 3 | Flaccid, superficial bullae; positive Nikolsky sign; skin sloughing in sheets |
Desquamation | Day 3 to 5 | Dry, flaking desquamation |
Resolution | Day 7 to 14 | Complete healing without scarring |
An important point: SSSS heals without scarring because the cleavage plane is above the basement membrane. The basal layer, dermal papillae, and adnexal structures remain intact, which allows complete regeneration of the epidermis.
03Diagnostic Workup
Clinical examination
Role
Best initial step
Expected Findings
Diffuse tender erythroderma, positive Nikolsky sign, perioral crusting, no mucosal involvement
Skin biopsy (frozen section)
Role
Most accurate / confirmatory test
Expected Findings
Intra-epidermal cleavage through the granular layer; no necrotic keratinocytes; minimal to no inflammatory infiltrate in the dermis
Culture of the primary infection site
Role
Identifies the causative organism
Expected Findings
S. aureus (phage group II) from nasopharynx, conjunctiva, umbilicus, or wound; NOT from the bullae
Bullae fluid culture
Role
Helps distinguish from bullous impetigo
Expected Findings
Sterile in generalized SSSS (toxin is hematogenous); positive in bullous impetigo (local infection)
Blood cultures
Role
Low yield in children
Expected Findings
Usually negative in pediatric SSSS; may be positive in neonatal or adult cases
Basic metabolic panel
Role
Supportive care monitoring
Expected Findings
Assess for dehydration, electrolyte abnormalities from transepidermal fluid loss
Test | Role | Expected Findings |
|---|---|---|
Clinical examination | Best initial step | Diffuse tender erythroderma, positive Nikolsky sign, perioral crusting, no mucosal involvement |
Skin biopsy (frozen section) | Most accurate / confirmatory test | Intra-epidermal cleavage through the granular layer; no necrotic keratinocytes; minimal to no inflammatory infiltrate in the dermis |
Culture of the primary infection site | Identifies the causative organism | S. aureus (phage group II) from nasopharynx, conjunctiva, umbilicus, or wound; NOT from the bullae |
Bullae fluid culture | Helps distinguish from bullous impetigo | Sterile in generalized SSSS (toxin is hematogenous); positive in bullous impetigo (local infection) |
Blood cultures | Low yield in children | Usually negative in pediatric SSSS; may be positive in neonatal or adult cases |
Basic metabolic panel | Supportive care monitoring | Assess for dehydration, electrolyte abnormalities from transepidermal fluid loss |
SSSS is primarily a clinical diagnosis. In a classic vignette, a young child with fever and irritability develops diffuse, tender erythema followed by superficial desquamation with a positive Nikolsky sign and no oral mucosal lesions. When this presentation is described, the diagnosis should be apparent before any labs are ordered.
The best initial test in an ambiguous or atypical case is a skin biopsy with frozen section. This can be performed rapidly and provides the critical histologic finding: an intra-epidermal split at the level of the granular layer with acantholysis but without keratinocyte necrosis. This is the finding that definitively separates SSSS from toxic epidermal necrolysis (TEN). In TEN, the biopsy shows full-thickness epidermal necrosis with a subepidermal split at the dermoepidermal junction. This distinction is extremely high-yield.
Cultures should be obtained from the suspected primary site of infection (the nasopharynx, umbilical stump, conjunctivae, or a wound), not from the bullae. The bullae in generalized SSSS are sterile because the disease is toxin-mediated at a distance. Culturing the bullae and finding no growth actually supports the diagnosis of SSSS over bullous impetigo, in which bullae cultures are positive.
Blood cultures are typically negative in pediatric SSSS and are not required for diagnosis. However, in neonates and immunocompromised adults, bacteremia is more common, and blood cultures should be drawn.
04Management and Treatment
Acute: Antibiotics
Intervention
IV nafcillin or oxacillin
Details
150 to 200 mg/kg/day IV divided every 6 hours (pediatric dosing)
If MRSA suspected
Intervention
IV vancomycin
Details
40 to 60 mg/kg/day IV divided every 6 hours; monitor trough levels
Toxin suppression adjunct
Intervention
Clindamycin (consider adding)
Details
25 to 40 mg/kg/day IV divided every 8 hours; inhibits ribosomal toxin production
Fluid management
Intervention
Aggressive IV fluid resuscitation
Details
Calculate fluid needs as with a burn patient; monitor urine output and electrolytes
Wound care
Intervention
Gentle, non-adherent dressings
Details
Avoid aggressive debridement; apply emollients to denuded areas; minimize friction
Pain management
Intervention
Analgesics
Details
Acetaminophen or ibuprofen for fever and pain; opioids if necessary for severe skin tenderness
Transition to oral therapy
Intervention
Oral dicloxacillin or cephalexin
Details
Once clinical improvement is seen (usually 48 to 72 hours); complete a total course of 7 to 10 days
Contraindicated
Intervention
Systemic corticosteroids
Details
Immunosuppression worsens the infection and delays toxin clearance
Phase | Intervention | Details |
|---|---|---|
Acute: Antibiotics | IV nafcillin or oxacillin | 150 to 200 mg/kg/day IV divided every 6 hours (pediatric dosing) |
If MRSA suspected | IV vancomycin | 40 to 60 mg/kg/day IV divided every 6 hours; monitor trough levels |
Toxin suppression adjunct | Clindamycin (consider adding) | 25 to 40 mg/kg/day IV divided every 8 hours; inhibits ribosomal toxin production |
Fluid management | Aggressive IV fluid resuscitation | Calculate fluid needs as with a burn patient; monitor urine output and electrolytes |
Wound care | Gentle, non-adherent dressings | Avoid aggressive debridement; apply emollients to denuded areas; minimize friction |
Pain management | Analgesics | Acetaminophen or ibuprofen for fever and pain; opioids if necessary for severe skin tenderness |
Transition to oral therapy | Oral dicloxacillin or cephalexin | Once clinical improvement is seen (usually 48 to 72 hours); complete a total course of 7 to 10 days |
Contraindicated | Systemic corticosteroids | Immunosuppression worsens the infection and delays toxin clearance |
The next best step when SSSS is suspected is to start empiric IV antistaphylococcal antibiotics immediately. The first-line agents are nafcillin or oxacillin (150 to 200 mg/kg/day IV, divided every 6 hours in children). These beta-lactamase-resistant penicillins target methicillin-sensitive S. aureus (MSSA), which is the most common cause.
If the patient comes from a setting with a high prevalence of community-acquired MRSA, or if the patient is critically ill or not responding to initial therapy, vancomycin (40 to 60 mg/kg/day IV, divided every 6 hours) should be used instead. Trough levels should be monitored and maintained between 15 and 20 mcg/mL for serious infections.
Adding clindamycin is a consideration that may appear on exams. Clindamycin works by inhibiting the bacterial ribosome (50S subunit), which directly suppresses the production of exfoliative toxins. This is the same rationale used for adding clindamycin in toxic shock syndrome. The antibiotic does not just kill bacteria; it reduces the ongoing production of the toxin that is driving the disease.
Supportive care is essential and mirrors the approach to thermal burns. The denuded skin results in significant transepidermal water loss, electrolyte imbalance, and thermoregulatory dysfunction. IV fluids should be calculated based on the estimated body surface area of involvement, and electrolytes and urine output should be monitored closely. Wound care should be gentle. Non-adherent dressings and bland emollients (such as petroleum-based ointments) are applied to denuded areas. Aggressive scrubbing or debridement is harmful because the superficial epidermis will regenerate on its own.
Systemic corticosteroids are contraindicated. This is a commonly tested point. Corticosteroids suppress the immune response, impair bacterial clearance, and may worsen outcomes. This is the opposite of TEN, in which immunosuppressive agents (such as cyclosporine) are sometimes considered.
Once the patient shows clinical improvement (resolution of fever, decreasing tenderness, no new bullae formation, typically after 48 to 72 hours), antibiotics can be transitioned to an oral regimen such as dicloxacillin or cephalexin to complete a total antibiotic course of 7 to 10 days.
Prognosis: In children, with appropriate antibiotic therapy, mortality is very low (less than 5%). The skin heals completely within 7 to 14 days without scarring. In contrast, adult SSSS, which occurs in the setting of renal failure or immunosuppression, carries a mortality rate of up to 60%, largely due to comorbid conditions and delayed diagnosis.
05Differential Diagnosis and Distractors
Toxic Epidermal Necrolysis (TEN)
Why It Is Similar
Both present with diffuse erythema, positive Nikolsky sign, and widespread skin sloughing
Key Discriminator
TEN is drug-induced (not infectious), involves mucous membranes, and biopsy shows full-thickness epidermal necrosis with a subepidermal cleavage plane. SSSS has no mucosal involvement and a superficial intra-epidermal split.
Stevens-Johnson Syndrome (SJS)
Why It Is Similar
Widespread skin lesions with desquamation; also has Nikolsky sign in severe cases
Key Discriminator
SJS involves targetoid lesions and prominent mucosal erosions (oral, ocular, genital); it is triggered by medications; body surface area involvement is less than 10%
Bullous Impetigo
Why It Is Similar
Also caused by S. aureus exfoliative toxins (same pathogenesis)
Key Discriminator
Bullous impetigo is localized (discrete bullae, often on trunk); bullae fluid is culture-positive; there is no diffuse erythroderma or systemic toxicity
Scarlet Fever
Why It Is Similar
Diffuse erythematous rash in a child with sandpaper texture; perioral involvement
Key Discriminator
Caused by Group A Streptococcus (not S. aureus); rash does not blister or slough; pharyngitis is present; circumoral pallor (not crusting); strawberry tongue; no Nikolsky sign
Pemphigus Vulgaris
Why It Is Similar
Flaccid bullae with positive Nikolsky sign; intra-epidermal cleavage
Key Discriminator
Primarily affects adults (middle-aged); targets desmoglein-3 (with or without Dsg-1), so mucous membranes are prominently involved (oral erosions are often the first sign); biopsy shows suprabasal acantholysis with IgG antibodies on direct immunofluorescence
Thermal/Chemical Burn
Why It Is Similar
Denuded, erythematous skin resembling a scald
Key Discriminator
History of trauma or exposure; distribution matches the pattern of contact; no Nikolsky sign in uninvolved skin; no preceding fever or distant infectious focus
Kawasaki Disease
Why It Is Similar
Desquamation, fever, and erythema in a young child
Key Discriminator
Desquamation in Kawasaki begins at the fingertips and toes during the convalescent phase (not diffuse sheet-like sloughing); other criteria include conjunctivitis, strawberry tongue, cervical lymphadenopathy, and changes in the extremities
Differential | Why It Is Similar | Key Discriminator |
|---|---|---|
Toxic Epidermal Necrolysis (TEN) | Both present with diffuse erythema, positive Nikolsky sign, and widespread skin sloughing | TEN is drug-induced (not infectious), involves mucous membranes, and biopsy shows full-thickness epidermal necrosis with a subepidermal cleavage plane. SSSS has no mucosal involvement and a superficial intra-epidermal split. |
Stevens-Johnson Syndrome (SJS) | Widespread skin lesions with desquamation; also has Nikolsky sign in severe cases | SJS involves targetoid lesions and prominent mucosal erosions (oral, ocular, genital); it is triggered by medications; body surface area involvement is less than 10% |
Bullous Impetigo | Also caused by S. aureus exfoliative toxins (same pathogenesis) | Bullous impetigo is localized (discrete bullae, often on trunk); bullae fluid is culture-positive; there is no diffuse erythroderma or systemic toxicity |
Scarlet Fever | Diffuse erythematous rash in a child with sandpaper texture; perioral involvement | Caused by Group A Streptococcus (not S. aureus); rash does not blister or slough; pharyngitis is present; circumoral pallor (not crusting); strawberry tongue; no Nikolsky sign |
Pemphigus Vulgaris | Flaccid bullae with positive Nikolsky sign; intra-epidermal cleavage | Primarily affects adults (middle-aged); targets desmoglein-3 (with or without Dsg-1), so mucous membranes are prominently involved (oral erosions are often the first sign); biopsy shows suprabasal acantholysis with IgG antibodies on direct immunofluorescence |
Thermal/Chemical Burn | Denuded, erythematous skin resembling a scald | History of trauma or exposure; distribution matches the pattern of contact; no Nikolsky sign in uninvolved skin; no preceding fever or distant infectious focus |
Kawasaki Disease | Desquamation, fever, and erythema in a young child | Desquamation in Kawasaki begins at the fingertips and toes during the convalescent phase (not diffuse sheet-like sloughing); other criteria include conjunctivitis, strawberry tongue, cervical lymphadenopathy, and changes in the extremities |
06Traps and High-Yield Pearls
The single most common way students get this diagnosis wrong is by confusing SSSS with TEN. Both present with a positive Nikolsky sign and widespread skin involvement, which makes them look similar on a superficial read of the vignette. The exam will almost always include a distinguishing detail, and the most reliable discriminator is mucosal involvement. If the vignette describes oral erosions, conjunctival involvement, or genital ulceration, that points toward TEN or SJS, not SSSS. If the vignette explicitly states that mucous membranes are spared, or simply does not mention any mucosal findings, that is your signal for SSSS.
The second trap involves the age of the patient. SSSS overwhelmingly affects neonates and children under 5 years old. If you see an adult with a similar presentation, the default answer should be TEN (which is drug-induced) unless the vignette highlights renal failure or immunosuppression, which would make adult SSSS plausible.
A third common mistake is culturing the wrong site. Students may be tempted to culture the bullae, but in generalized SSSS, the bullae are sterile. The organism lives at the distant primary site of infection. If a vignette asks for the best diagnostic step and includes "culture the blister fluid" as an option, that is a distractor.
Finally, remember that corticosteroids are contraindicated in SSSS. This is sometimes offered as a tempting answer choice because corticosteroids are used in many other inflammatory skin conditions. In SSSS, immunosuppression worsens the underlying staphylococcal infection.
The core competency being tested with SSSS questions is the ability to distinguish between toxin-mediated superficial epidermal disease and immune-mediated full-thickness epidermal destruction, using mucosal involvement, patient demographics, biopsy findings, and the drug history as the key differentiating factors.